Sanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Sanctuary Advisors LLC acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 104,924 shares of the company’s stock, valued at approximately $474,000. Sanctuary Advisors LLC owned approximately 0.20% of Zevra Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD purchased a new position in Zevra Therapeutics during the 1st quarter worth approximately $64,000. The Manufacturers Life Insurance Company grew its position in Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares in the last quarter. Virtu Financial LLC purchased a new position in Zevra Therapeutics during the 4th quarter worth approximately $177,000. Jacobs Levy Equity Management Inc. grew its position in Zevra Therapeutics by 102.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after purchasing an additional 17,557 shares in the last quarter. Finally, Rhumbline Advisers grew its position in Zevra Therapeutics by 17.9% during the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after purchasing an additional 8,619 shares in the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Trading Up 1.0 %

Zevra Therapeutics stock opened at $8.46 on Thursday. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. Zevra Therapeutics, Inc. has a 12 month low of $3.89 and a 12 month high of $8.95. The company’s fifty day simple moving average is $7.46 and its 200-day simple moving average is $5.91. The stock has a market cap of $354.08 million, a P/E ratio of -6.27 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The business had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. During the same period in the previous year, the firm posted ($0.15) EPS. As a group, sell-side analysts forecast that Zevra Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on ZVRA. Roth Mkm lifted their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. JMP Securities initiated coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price objective on the stock. Guggenheim initiated coverage on shares of Zevra Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $20.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Finally, William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Zevra Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $20.83.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.